問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Hematology & Oncology

National Health Research Institutes (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of General Internal Medicine

更新時間:2023-09-19

蔡慧珍Tsai, Hui-Jen
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

篩選

List

1Cases

2019-06-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
  • Condition/Disease

    Differentiated Thyroid Cancer

  • Test Drug

    Cabozantinib (XL184) 20mg and 60mg tablet

Participate Sites
4Sites

Recruiting4Sites